



NEWS RELEASE

# Natera Named to Fast Company's Next Big Things in Tech List

2025-10-16

Selection based on Natera's Signatera™ test and its impact on cancer care

AUSTIN, Texas--(BUSINESS WIRE)-- **Natera, Inc.** (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Company's 2025 **Next Big Things in Tech** list. Honored for its Signatera personalized molecular residual disease (MRD) test, Natera was one of five companies recognized in the health and medicine category.

This annual program by Fast Company highlights innovative technologies that have the potential to impact their respective industries. Developed by established companies, startups, or research teams, these technologies are featured for their potential to revolutionize the lives of consumers, businesses, and society overall.

Custom-built for each individual, Signatera is a blood test that uses circulating tumor DNA to detect and quantify cancer left in the body to identify recurrence earlier than standard of care tools and help optimize treatment decisions. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 140 peer-reviewed papers. Today, it is ordered by more than 50% of U.S. oncologists.

"As one of the most important tools to fight cancer today, Signatera is transforming how we detect, monitor, and ultimately treat the disease," said Steve Chapman, chief executive officer of Natera. "This recognition from Fast Company underscores the impact of molecular residual disease testing, as well as the promise of further innovation still ahead for patients worldwide. Congratulations to everyone at Natera for this honor."

"Next Big Things in Tech is both a snapshot of the most interesting tech of the moment and a crystal ball that



predicts the next several years,” says Brendan Vaughan, editor-in-chief of Fast Company. “We’re excited to share this list with our readers, and we congratulate the winners for their vision and innovation.”

For more information or to view the complete list of honorees, visit [here](#).

## About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit [www.natera.com](http://www.natera.com).

## About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at [fastcompany.com](http://fastcompany.com).

## Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at [www.natera.com/investors](http://www.natera.com/investors) and [www.sec.gov](http://www.sec.gov).

Investor Relations: Mike Brophy, CFO, Natera, Inc., [investor@natera.com](mailto:investor@natera.com)

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [pr@natera.com](mailto:pr@natera.com)

Source: Natera, Inc.